CF
ZBIO

Corebridge Financial’s Zenas BioPharma ZBIO Stock Holding History

Corebridge Financial’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,529
Closed -$59.5K – 2952
2025
Q1 		$59.5K Sell
7,529
-111
-1% -$869 ﹤0.01% 2671
2024
Q4 		$62.6K Buy
+7,640
New +$119K ﹤0.01% 2764

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Corebridge Financial's ZBIO Position: Q2 2025 in Review

Corebridge Financial sold out of Zenas BioPharma (ZBIO) in Q2 2025, closing a stake of 7,529 shares — an estimated $59.5K sold.

Corebridge Financial first reported a position in ZBIO in Q4 2024 and held it in 2 quarters. The position peaked at $62.6K in Q4 2024. 73 funds tracked by Wall St. Rank hold ZBIO as of Q2 2025.

  • Corebridge Financial reported no remaining Zenas BioPharma position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 7,529 Zenas BioPharma shares in Q2 2025, an estimated $59.5K.
  • Corebridge Financial first reported a position in Zenas BioPharma in Q4 2024 and held it in 2 quarters.
  • Corebridge Financial's Zenas BioPharma position peaked at $62.6K in Q4 2024.
  • 73 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.